INDV vs. MLTX, MOR, EVO, ARWR, IDYA, ACAD, SMMT, HCM, MRUS, and CORT
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Evotec (EVO), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), ACADIA Pharmaceuticals (ACAD), Summit Therapeutics (SMMT), HUTCHMED (HCM), Merus (MRUS), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceutical preparations" industry.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Indivior (NASDAQ:INDV) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
MoonLake Immunotherapeutics presently has a consensus target price of $74.46, indicating a potential upside of 75.24%. Indivior has a consensus target price of $36.00, indicating a potential upside of 104.78%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
Indivior has a net margin of 0.44% compared to Indivior's net margin of 0.00%. MoonLake Immunotherapeutics' return on equity of 700.00% beat Indivior's return on equity.
In the previous week, Indivior had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 7 mentions for Indivior and 6 mentions for MoonLake Immunotherapeutics. Indivior's average media sentiment score of 0.50 beat MoonLake Immunotherapeutics' score of -0.73 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
Indivior has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 15.3% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
MoonLake Immunotherapeutics received 43 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 76.27% of users gave MoonLake Immunotherapeutics an outperform vote.
Summary
Indivior beats MoonLake Immunotherapeutics on 11 of the 17 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
